Clinical Trials
21
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability
- Conditions
- Healthy Volunteers
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT04735822
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, England, United Kingdom
Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025
- Conditions
- Autoimmune DiseasesFibrosis
- Interventions
- Drug: [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdoseDrug: [14C]-KD025 200 mg capsule
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT03907540
- Locations
- 🇬🇧
Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom
Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers
- Conditions
- Drug-drug InteractionAutoimmune DiseasesFibrotic Disease
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 73
- Registration Number
- NCT03530995
- Locations
- 🇬🇧
Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT03096080
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT02852967
- Locations
- 🇺🇸
Alliance Dermatology and Mohs Center, Phoenix, Arizona, United States
🇺🇸University of California, Irvine - Dermatology Clinical Research Center, Irvine, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next